Personalized weight loss? study links genes, gut bugs to tirzepatide success

NCT ID NCT07650149

Recruiting now Knowledge-focused Sponsor: Jan Kochanowski University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a person's genetics, gut microbiome, and behaviors influence how well they tolerate and respond to the weight-loss drug tirzepatide. Researchers will follow 200 overweight or obese adults for up to 12 months, tracking weight changes, side effects, and whether they stay on the medication. The goal is to find clues that could help tailor obesity treatment to each individual.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide
What this could lead to: If successful, this could help doctors personalize obesity treatment by predicting who will benefit most from tirzepatide based on their genes and gut bacteria.
What could go wrong: This is an observational study, not a treatment trial. It won't prove that tirzepatide works, only that certain factors may influence its effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETICS OBESITY OBESITY & OVERWEIGHT

Contacts and locations

Locations

Luxmed sp zoo
RECRUITING

Warsaw, Poland
Waga Zmiany
RECRUITING

Krakow, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.